What is claimed is:

1. Use of a composition comprising an effective amount of cedazuridine and an effective amount of decitabine, in the manufacture of a medicament for treating myelodysplastic syndromes (MDS) in a subject in need thereof,

wherein the effective amount of cedazuridine and the effective amount of decitabine to be administered increases survival and/or leukemia-free survival of the subject to about 130% to about 400% relative to survival or leukemia-free survival, respectively, obtained by treatment with a hypomethylating agent alone; and/or provides the subject with a survival and/or leukemia-free survival of at least about 28, 30, 32, or 34 months.

2. The use according to claim 1, wherein the effective amount of cedazuridine and the effective amount of decitabine are to be administered on days 1-5 of a 28-day cycle.

3. The use according to claim 1, wherein the effective amount of cedazuridine and the effective amount of the decitabine are present in a solid oral dosage form that comprises 100 mg cedazuridine, 35 mg decitabine, and at least one pharmaceutically acceptable excipient.

4. The use according to claim 1,

wherein the effective amount of cedazuridine and the effective amount of decitabine to be administered increases survival and/or leukemia-free survival of the subject to about 200% to about 400% relative to survival or leukemia-free survival, respectively, obtained by providing best supportive care alone.

5. Use of a composition comprising an effective amount of cedazuridine and an effective amount of decitabine, in the manufacture of a medicament for treating lower-risk MDS in a subject in need thereof,

wherein the effective amount of cedazuridine and the effective amount of decitabine to be administered increases survival and/or leukemia-free survival of the subject to about 130% to about 400% relative to survival or leukemia-free survival, respectively, obtained by treatment with a hypomethylating agent alone; and/or provides the subject with a survival and/or leukemia-free survival of at least about 28, 30, 32, or 34 months.

6. The use according to claim 5, wherein the effective amount of cedazuridine and the effective amount of decitabine are to be administered on days 1-5 of a 28-day cycle.

7. The use according to claim 5, wherein the effective amount of cedazuridine and the effective amount of the decitabine are present in a solid oral dosage form that comprises 100 mg cedazuridine, 35 mg decitabine, and at least one pharmaceutically acceptable excipient.

8. The use according to claim 5,

wherein the effective amount of cedazuridine and the effective amount of decitabine to be administered increases survival and/or leukemia-free survival of the subject to about 200% to about 400% relative to survival or leukemia-free survival, respectively, obtained by providing best supportive care alone.

9. Use of a composition comprising an effective amount of cedazuridine and an effective amount of decitabine, in the manufacture of a medicament for treating chronic myelomonocytic leukemia (CMML) in a subject in need thereof,

wherein the effective amount of cedazuridine and the effective amount of decitabine to be administered increases survival and/or leukemia-free survival of the subject to about 130% to about 400% relative to the survival or leukemia-free survival, respectively, obtained by treatment with a hypomethylating agent alone; and/or provides the subject with a survival and/or leukemia-free survival of at least about 28, 30, 32, or 34 months.

10. The use according to claim 9, wherein the effective amount of cedazuridine and the effective amount of decitabine are to be administered on days 1-5 of a 28-day cycle.

11. The use according to claim 9, wherein the effective amount of cedazuridine and the effective amount of the decitabine are present in a solid oral dosage form that comprises 100 mg cedazuridine, 35 mg decitabine, and at least one pharmaceutically acceptable excipient.

12. The use according to claim 9,

wherein the effective amount of cedazuridine and the effective amount of decitabine to be administered increases survival and/or leukemia-free survival of the subject to about 200% to about 375% relative to survival or leukemia-free survival, respectively, obtained by providing best supportive care alone.

13. Use of a composition comprising an effective amount of cedazuridine and an effective amount of decitabine, in the manufacture of a medicament for treating MDS or CMML in a subject having a *TP53* mutation in need thereof,
wherein the effective amount of cedazuridine and the effective amount of decitabine to be administered increases survival and/or leukemia-free survival of the subject to about 130% to about 400% relative to survival or leukemia-free survival, respectively, obtained by treatment with a hypomethylating agent alone; and/or provides the subject with a survival and/or leukemia-free survival of at least about 20, 22, 24, 26, 28, 30, 32, 34, or 36 months for a subject with a mono-allelic *TP53* mutation or at least about 10, 12,14, 16,18, or 20 months for a subject with a bi-allelic *TP53* mutation.

14. The use according to claim 13, wherein the effective amount of cedazuridine and the effective amount of decitabine are to be administered on days 1-5 of a 28-day cycle.

15. The use according to claim 13, wherein the effective amount of cedazuridine and the effective amount of the decitabine are present in a solid oral dosage form that comprises 100 mg cedazuridine, 35 mg decitabine, and at least one pharmaceutically acceptable excipient.

16. The use according to claim 13,
wherein the effective amount of cedazuridine and the effective amount of decitabine to be administered increases survival and/or leukemia-free survival of the subject to about 200% to about 400% relative to survival or leukemia-free survival, respectively, obtained by providing best supportive care alone.

17. A kit comprising one or more doses (e.g., 1, 2, 3, 4, or 5) of an effective amount of cedazuridine (e.g., 100 mg) and one or more doses (e.g., 1, 2, 3, 4, or 5) of an effective amount of decitabine (e.g., 35 mg) for the use according to claims 1-16.

18. A combination comprising one or more doses (e.g., 1, 2, 3, 4, or 5) of an effective amount of cedazuridine (e.g., 100 mg) and one or more doses (e.g., 1, 2, 3, 4, or 5) of an effective amount of decitabine (e.g., 35 mg) for the use according to claims 1-16.